Related Experiment Videos
Temozolomide as first-line agent in treating high-grade gliomas: phase II study.
S Chibbaro1, L Benvenuti, A Caprio
1Department of Neurosurgery, Livorno Hospital, Italy. schibbaro@hotmail.com
Journal of Neuro-Oncology
|April 10, 2004
Summary
Temozolomide shows efficacy in treating high-grade gliomas, improving survival and quality of life. This oral chemotherapy agent demonstrated a safe profile with no major adverse events in patients with malignant gliomas.
Area of Science:
- Oncology
- Pharmacology
Background:
- High-grade gliomas are aggressive brain tumors with limited treatment options.
- Temozolomide is an oral alkylating agent with demonstrated efficacy in preclinical and early-phase studies.
Purpose of the Study:
- To evaluate the efficacy and safety of temozolomide in patients with malignant gliomas.
- To assess temozolomide's impact on overall survival (OS), progression-free survival (PFS), and health-related quality of life (HQL).
Main Methods:
- A study involving 42 patients with newly diagnosed glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma.
- Patients were treated with temozolomide, with a mean follow-up of 12 months.
Main Results:
- The overall response rate was 40%, with 24% showing disease stabilization.
- Median PFS was 8.35 months and median OS was 14.1 months.
- Karnofsky scores improved in all patients, indicating enhanced performance status and quality of life.
Conclusions:
- Temozolomide is an effective first-line, single-agent treatment for high-grade gliomas.
- The drug exhibits a favorable safety profile with no treatment-related discontinuations or major adverse events.
- Temozolomide demonstrated significant benefits in improving health-related quality of life for patients.